CT-039 Health-Related Quality of Life Following Allogeneic Hematopoietic Stem Cell Transplantation With Omidubicel Versus Standard Umbilical Cord Blood
Chenyu Lin(Duke University), Anthony D. Sung(Duke University), Rocio Manghani, Mitchell E. Horwitz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Corey Cutler(Harvard University), James Signorovitch(Analysis Group (United States)), Claudio G. Brunstein(Hotel Dieu Hospital), Gautam Sajeev(Analysis Group (United States)), Rabi Hanna(Cleveland Clinic), Caroline A. Lindemans(University Medical Center Utrecht), Guillermo Sanz(Instituto de Salud Carlos III), Einat Galamidi-Cohen(Gamida Cell (Israel)), Andrew R. Rezvani(Stanford Blood Center), Smitha Sivaraman, Liang Piu Koh(National University Cancer Institute, Singapore), Richard T. Maziarz(Oregon Health & Science University), Qing Liu(Analysis Group (United States)), William Ying Khee Hwang(Singapore General Hospital), Yan Song(Analysis Group (United States)), Patrick J. Stiff(Loyola University Medical Center)
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k